FDA Puts on Hold Phase 1 Cellectis Trial Testing CAR T-cell Therapy UCARTCS1A

Home / Blog / FDA Puts on Hold Phase 1 Cellectis Trial Testing CAR T-cell Therapy UCARTCS1A
FDA Puts on Hold Phase 1 Cellectis Trial Testing CAR T-cell Therapy UCARTCS1A
September 15, 2020September 15, 2020
0

A Phase 1 trial assessing Cellectis’ investigational CAR T-cell therapy, UCARTCS1A, for the treatment of relapsed or refractory multiple myeloma has been placed on hold by the U.S. Food and Drug Administration (FDA), the company announced in a press release. The MELANI-01 study (NCT04142619) was assessing the safety and clinical activity of different doses of UCARTCS1A, administered in a single infusion, with the aim of determining the optimal dose for further testing. The clinical hold came…

You must be logged in to read/download the full post.

The post FDA Puts on Hold Phase 1 Cellectis Trial Testing CAR T-cell Therapy UCARTCS1A appeared first on BioNewsFeeds.